Prudential Financial Inc. lowered its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 5.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 581,488 shares of the biopharmaceutical company’s stock after selling 32,830 shares during the quarter. Prudential Financial Inc. owned 1.30% of Vanda Pharmaceuticals worth $9,478,000 as of its most recent filing with the SEC.
A number of other institutional investors have also added to or reduced their stakes in VNDA. Point72 Asset Management L.P. lifted its holdings in Vanda Pharmaceuticals by 1,544.3% in the first quarter. Point72 Asset Management L.P. now owns 2,484,500 shares of the biopharmaceutical company’s stock valued at $34,783,000 after acquiring an additional 2,333,400 shares during the period. FMR LLC lifted its holdings in Vanda Pharmaceuticals by 60.7% in the first quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock valued at $22,416,000 after acquiring an additional 604,900 shares during the period. Vanguard Group Inc. lifted its holdings in Vanda Pharmaceuticals by 26.4% in the first quarter. Vanguard Group Inc. now owns 2,494,347 shares of the biopharmaceutical company’s stock valued at $34,920,000 after acquiring an additional 521,669 shares during the period. Nexthera Capital LP acquired a new stake in Vanda Pharmaceuticals in the first quarter valued at $7,171,000. Finally, Renaissance Technologies LLC lifted its holdings in Vanda Pharmaceuticals by 65.3% in the first quarter. Renaissance Technologies LLC now owns 939,250 shares of the biopharmaceutical company’s stock valued at $13,150,000 after acquiring an additional 370,900 shares during the period. 86.49% of the stock is owned by institutional investors.
Vanda Pharmaceuticals Inc. (VNDA) opened at 17.25 on Wednesday. Vanda Pharmaceuticals Inc. has a 1-year low of $12.70 and a 1-year high of $18.00. The stock’s 50 day moving average price is $16.25 and its 200 day moving average price is $15.09. The firm’s market cap is $773.80 million.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The business had revenue of $42.06 million during the quarter, compared to analysts’ expectations of $40.31 million. During the same quarter last year, the business posted $0.01 earnings per share. The company’s quarterly revenue was up 16.7% on a year-over-year basis. Equities research analysts predict that Vanda Pharmaceuticals Inc. will post ($0.44) EPS for the current year.
A number of equities research analysts have commented on the company. BidaskClub downgraded Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Oppenheimer Holdings, Inc. set a $21.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. HC Wainwright set a $18.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Piper Jaffray Companies set a $23.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $21.00 target price on shares of Vanda Pharmaceuticals in a report on Thursday, May 25th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $21.25.
TRADEMARK VIOLATION NOTICE: This report was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/2888100/vanda-pharmaceuticals-inc-vnda-holdings-reduced-by-prudential-financial-inc.html.
Vanda Pharmaceuticals Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.